Health Canada Gave CannTrust (TSX:TRST) a Lifeline: Could the Stock Recover?

CannTrust Holdings Inc. (TSX:TRST)(NYSE:CTST) stock could surge if management quickly capitalizes on Health Canada’s lenience.

edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Troubled cannabis stock CannTrust Holdings (TSX:TRST)(NYSE:CTST) is battling for survival after illegally growing cannabis in the latest scandal to rock the Canadian marijuana industry. Instead of a straight licence revocation for the violation, Health Canada partially suspended the company’s sales and processing licences, and there are hints for their potential reinstatement once the cause for suspension is no longer present.

Given the seemingly lenient treatment by the industry regulator, the company has a fighting chance to survive a total collapse.

What’s required for survival?

For CannTrust stock to recover, the company has to retain its cannabis licences, preserve cash resources until sales resume, hope to retain its client base, and minimize regulatory penalties while vigorously defending investor lawsuits.

Until such a time the regulator is satisfied that the cause for licence suspension no longer exists and licences get restored, management has to tightly sail the damaged ship. The big question is if the company can survive a total collapse before its licences are restored.

A case for licence restoration

The company promptly set up a task force to proactively deal with the crisis and craft ways to quickly bring the company back into full regulatory compliance, and Health Canada could have softened its stance in acknowledgement of signs of progress and sincerity on the part of new management.

Given that two senior executives were fired for cause, and company voluntarily halted all product sales in July while making frantic efforts to rectify the situation, the latest suspension of licences has no significant financial impact to the company, for now.

In my personal view, it seems like the company’s constantly reported engagement efforts with Health Canada to regain the regulator’s trust are beginning to pay off. It’s increasingly possible that the company could get its licences fully reinstated.

Cannabis is already a highly regulated industry with very high minimum security and operating standards for licensed producers. The assurances that the company was asked to give to the regulatory body for its licences to be restored are mere standard industry practices; there’s nothing sinister or punitive about them.

It’s required that a marijuana producer should have strict measures to control product movement within and out of sites. Companies have to naturally promote personnel knowledge of the law and industry standards, while tight record retention and inventory tracking systems come standard for every serious business, and this is what the company has to prove to get its licences reinstated.

That’s an easy task for a serious management team.

Inventory could have been replenished

The company was allowed to continue growing and harvesting current crop batches but will not be allowed to plant new ones until licences are restored. Actually, we know that grow operations continued undisturbed since the scandal broke out; the company could easily have replenished its clean inventory levels, even if 53% of June 30th inventory could be written off.

The challenge is how fast the company could return to historical sales levels if licences are restored and whether traditional markets will be ready to forgive and forget.

Could shares recover?

It’s still too early to conclude on licence restoration, but if the special task force is as effective as it sounds in press releases, CannTrust could be back in regulatory compliance relatively quickly before its $250 million cash balance at June 30 gets depleted.

Management did well to quickly prepay a $13 million outstanding mortgage loan that required regular interest payments, while the company’s decision to reduce its staff by 20% will save millions in remuneration expenses. Any small savings are necessary during this period of zero revenue generation.

A recovery is still possible, but the income statement is totally busted, and the balance sheet’s health is obviously deteriorating. Add to this the threat of further regulatory penalties and investor lawsuits, and you have a significantly uncertain future for the cannabis firm, but with a huge potential for outsized gains if licences are restored in good time.

That said, buying the stock today is still more a gamble on regulatory decisions and a strategic buyout than a show of faith in TRST’s financial position.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »